Advertisement
Screener

Tempest Therapeutics, Inc. (TPST) Income (Loss) from Equity Method Investments

2.8 / 5 stars · 68/120 Roast Me

Tempest Therapeutics, Inc. Income (Loss) from Equity Method Investments

Tempest Therapeutics, Inc. (TPST) reported Income (Loss) from Equity Method Investments of -$2.00 thousand for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.

Discontinued › Income Statement › Other Income

us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2018-11-09

  • Tempest Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2018-09-30 was -$2.00K.
  • Tempest Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2018-06-30 was -$4.00K.
  • Tempest Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2018-03-31 was $0.00.
  • Tempest Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2017-12-31 was -$3.00K.
  • Tempest Therapeutics, Inc. income (loss) from equity method investments for fiscal 2017 was -$1.02M.
  • Tempest Therapeutics, Inc. income (loss) from equity method investments for fiscal 2016 was -$1.54M.
  • Tempest Therapeutics, Inc. income (loss) from equity method investments for fiscal 2015 was -$1.56M.
  • Tempest Therapeutics, Inc. income (loss) from equity method investments for fiscal 2014 was -$1.58M.
Period endIncome (Loss) from Equity Method Investments 3 monthIncome (Loss) from Equity Method Investments 6 monthIncome (Loss) from Equity Method Investments 9 monthIncome (Loss) from Equity Method Investments 12 monthIncome (Loss) from Equity Method Investments 36 month
2018-09-30-$2.00K
10-Q · filed 2018-11-09
-$6.00K
derived: sum of 2 quarters · filed 2018-11-09
-$6.00K
10-Q · filed 2018-11-09
-$9.00K
derived: sum of 4 quarters · filed 2018-11-09
2018-06-30-$4.00K
10-Q · filed 2018-08-09
-$4.00K
10-Q · filed 2018-08-09
-$7.00K
derived: sum of 3 quarters · filed 2018-08-09
-$147.00K
derived: sum of 4 quarters · filed 2018-11-09
2018-03-31$0.00
10-Q · filed 2018-05-03
-$3.00K
derived: sum of 2 quarters · filed 2018-05-03
-$143.00K
derived: sum of 3 quarters · filed 2018-11-09
-$597.00K
derived: sum of 4 quarters · filed 2018-11-09
2017-12-31-$3.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
-$143.00K
derived: sum of 2 quarters · filed 2018-11-09
-$597.00K
derived: sum of 3 quarters · filed 2018-11-09
-$1.02M
10-K · filed 2018-03-15
2017-09-30-$140.00K
10-Q · filed 2018-11-09
-$594.00K
derived: sum of 2 quarters · filed 2018-11-09
-$1.01M
10-Q · filed 2018-11-09
-$1.39M
derived: sum of 4 quarters · filed 2018-11-09
2017-06-30-$454.00K
10-Q · filed 2018-08-09
-$875.00K
10-Q · filed 2018-08-09
-$1.25M
derived: sum of 3 quarters · filed 2018-08-09
-$1.61M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31-$421.00K
10-Q · filed 2018-05-03
-$792.00K
derived: sum of 2 quarters · filed 2018-05-03
-$1.16M
derived: sum of 3 quarters · filed 2018-05-03
-$1.57M
derived: sum of 4 quarters · filed 2018-05-03
2016-12-31-$371.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
-$735.00K
derived: sum of 2 quarters · filed 2018-03-15
-$1.15M
derived: sum of 3 quarters · filed 2018-03-15
-$1.54M
10-K · filed 2018-03-15
2016-09-30-$364.00K
10-Q · filed 2017-11-02
-$780.00K
derived: sum of 2 quarters · filed 2017-11-02
-$1.17M
10-Q · filed 2017-11-02
-$1.56M
derived: sum of 4 quarters · filed 2018-03-15
2016-06-30-$416.00K
10-Q · filed 2016-08-04
-$807.00K
10-Q · filed 2017-08-03
-$1.19M
derived: sum of 3 quarters · filed 2018-03-15
-$1.51M
derived: sum of 4 quarters · filed 2018-03-15
2016-03-31-$391.00K
10-Q · filed 2017-05-09
-$776.00K
derived: sum of 2 quarters · filed 2018-03-15
-$1.09M
derived: sum of 3 quarters · filed 2018-03-15
-$1.48M
derived: sum of 4 quarters · filed 2018-03-15
2015-12-31-$385.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
-$701.00K
derived: sum of 2 quarters · filed 2018-03-15
-$1.09M
derived: sum of 3 quarters · filed 2018-03-15
-$1.56M
10-K · filed 2018-03-15
2015-09-30-$316.00K
10-Q · filed 2016-11-03
-$705.00K
derived: sum of 2 quarters · filed 2016-11-03
-$1.18M
10-Q · filed 2016-11-03
-$1.84M
derived: sum of 4 quarters · filed 2017-03-02
2015-06-30-$389.00K
10-Q · filed 2016-08-04
-$860.00K
10-Q · filed 2016-08-04
-$1.53M
derived: sum of 3 quarters · filed 2017-03-02
-$2.05M
derived: sum of 4 quarters · filed 2017-03-02
2015-03-31-$471.00K
10-Q · filed 2016-05-05
-$1.14M
derived: sum of 2 quarters · filed 2017-03-02
-$1.66M
derived: sum of 3 quarters · filed 2017-03-02
-$1.96M
derived: sum of 4 quarters · filed 2017-03-02
2014-12-31-$668.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02
-$1.19M
derived: sum of 2 quarters · filed 2017-03-02
-$1.49M
derived: sum of 3 quarters · filed 2017-03-02
-$1.58M
10-K · filed 2017-03-02
2014-09-30-$523.00K
10-Q · filed 2015-11-05
-$818.00K
derived: sum of 2 quarters · filed 2015-11-05
-$915.00K
10-Q · filed 2015-11-05
2014-06-30-$295.00K
10-Q · filed 2015-08-10
-$392.00K
10-Q · filed 2015-08-10
2014-03-31-$97.00K
10-Q · filed 2015-05-11
-$97.00K
10-Q · filed 2014-05-08
2013-12-31$0.00
10-K · filed 2016-02-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
BIOVIE INC. (BIVI)United States$0.012B
MUSTANG BIO, INC. (MBIO)United States$0.013B
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B